KR101761324B1 - 통증 치료 - Google Patents

통증 치료 Download PDF

Info

Publication number
KR101761324B1
KR101761324B1 KR1020117017019A KR20117017019A KR101761324B1 KR 101761324 B1 KR101761324 B1 KR 101761324B1 KR 1020117017019 A KR1020117017019 A KR 1020117017019A KR 20117017019 A KR20117017019 A KR 20117017019A KR 101761324 B1 KR101761324 B1 KR 101761324B1
Authority
KR
South Korea
Prior art keywords
pain
csf
ser
leu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117017019A
Other languages
English (en)
Korean (ko)
Other versions
KR20110117659A (ko
Inventor
죤 알랜 해밀튼
앤드류 데이빗 쿡
Original Assignee
더 유니버시티 오브 멜버른
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 유니버시티 오브 멜버른 filed Critical 더 유니버시티 오브 멜버른
Publication of KR20110117659A publication Critical patent/KR20110117659A/ko
Application granted granted Critical
Publication of KR101761324B1 publication Critical patent/KR101761324B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020117017019A 2008-12-22 2009-12-21 통증 치료 Active KR101761324B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13968708P 2008-12-22 2008-12-22
US61/139,687 2008-12-22
US16449109P 2009-03-30 2009-03-30
US61/164,491 2009-03-30
PCT/AU2009/001671 WO2010071923A1 (en) 2008-12-22 2009-12-21 Pain treatment

Publications (2)

Publication Number Publication Date
KR20110117659A KR20110117659A (ko) 2011-10-27
KR101761324B1 true KR101761324B1 (ko) 2017-07-25

Family

ID=42286785

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117017019A Active KR101761324B1 (ko) 2008-12-22 2009-12-21 통증 치료

Country Status (12)

Country Link
US (3) US8475796B2 (enExample)
EP (2) EP2387418B1 (enExample)
JP (3) JP5674677B2 (enExample)
KR (1) KR101761324B1 (enExample)
CN (2) CN108014335A (enExample)
AU (2) AU2009329811B2 (enExample)
BR (1) BRPI0918103A2 (enExample)
CA (1) CA2747206C (enExample)
ES (2) ES2978209T3 (enExample)
HK (2) HK1255046A1 (enExample)
RU (2) RU2630969C2 (enExample)
WO (1) WO2010071923A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2978209T3 (es) * 2008-12-22 2024-09-09 Univ Melbourne Tratamiento del dolor
US9243061B2 (en) 2008-12-22 2016-01-26 University Of Melbourne Osteoarthritis treatment
KR20210021153A (ko) * 2012-09-20 2021-02-24 모르포시스 아게 류마티스 관절염에 대한 치료
CN109999195A (zh) 2012-09-20 2019-07-12 莫弗系统股份公司 类风湿关节炎的治疗
EP2914289B1 (en) * 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US20160024200A1 (en) * 2013-03-14 2016-01-28 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
KR20220045064A (ko) 2013-08-30 2022-04-12 다케다 야쿠힌 고교 가부시키가이샤 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체
PL3328887T3 (pl) * 2016-09-19 2021-12-27 I-Mab Biopharma (Hangzhou) Co., Ltd. Przeciwciała anty-gm-csf i ich zastosowania
CN107840885B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
CN120093288B (zh) * 2025-05-08 2025-07-11 中国农业大学烟台研究院 一种牲畜生理行为监测方法及系统

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2062975A1 (en) * 1989-07-14 1991-01-15 Gail F. Seelig Antagonists of gm-csf derived from the carboxyl terminus
DE69031914T2 (de) 1989-08-11 1998-07-30 Amrad Corp. Ltd., Kew, Victoria Rezeptor für granulozyten-macrophagen-koloniestimulierungsfaktor und seine derivate
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
CA2149881A1 (en) * 1992-11-19 1994-05-26 Paul T. Jubinsky Antibodies for gm-csf receptor and uses thereof
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
SE0102067D0 (sv) 2001-06-11 2001-06-11 A & Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
US20060067938A1 (en) 2001-10-26 2006-03-30 Sherif Daouti Methods for the treatment of osteoarthritis and compositions thereof
ATE444308T1 (de) 2002-02-13 2009-10-15 Ludwig Inst Cancer Res Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
AU2002950957A0 (en) * 2002-08-23 2002-09-12 The Walter And Eliza Hall Institute Of Medical Research A method of treatment and prophylaxis
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US20040241755A1 (en) 2003-06-02 2004-12-02 Pfizer Inc. Human cell assay to determine effect of sample compounds on Col2 enhancer expression
JP4825667B2 (ja) 2004-03-31 2011-11-30 一和 中尾 関節炎症治療剤又は予防剤
EP1593690B1 (en) 2004-05-05 2009-07-01 Micromet AG Preparation of ScFv antibody fragments
EA013162B1 (ru) 2005-04-18 2010-02-26 Микромет Аг Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
BRPI0610796B8 (pt) * 2005-05-18 2021-05-25 Morphosys Ag anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CA2629850A1 (en) 2005-12-01 2007-06-07 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
CN101501070B (zh) * 2006-02-08 2013-12-25 诺福泰克公司 抗原性gm-csf肽和针对gm-csf的抗体
CN103641916A (zh) 2006-03-27 2014-03-19 医学免疫有限公司 Gm-csf受体结合元件
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
NZ598345A (en) * 2006-11-21 2013-09-27 Kalobios Pharmaceuticals Inc Methods of treating chronic inflammatory diseases using a gm-csf antagonist
WO2008080134A2 (en) 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
CN101687926A (zh) 2007-05-23 2010-03-31 哮喘和气道Crc有限公司 中和抗体
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
EP2217626A4 (en) 2007-11-12 2011-06-22 Crc For Asthma And Airways Ltd EPITOP FOR NEUTRALIZING ANTIBODIES
TWI434854B (zh) 2007-11-13 2014-04-21 Evec Inc 結合ｈＧＭ－ＣＳＦ的單株抗體以及包含其之醫學組成物
JP5688363B2 (ja) 2008-04-28 2015-03-25 カロバイオス ファーマシューティカルズ インコーポレイティッド 顆粒球−マクロファージコロニー刺激因子に対する抗体
ES2978209T3 (es) 2008-12-22 2024-09-09 Univ Melbourne Tratamiento del dolor
US9243061B2 (en) 2008-12-22 2016-01-26 University Of Melbourne Osteoarthritis treatment
SG175305A1 (en) 2009-04-23 2011-11-28 Theraclone Sciences Inc Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies

Also Published As

Publication number Publication date
WO2010071923A1 (en) 2010-07-01
ES2978209T3 (es) 2024-09-09
AU2009329811A1 (en) 2010-07-01
RU2712166C2 (ru) 2020-01-24
CN108014335A (zh) 2018-05-11
EP2387418A1 (en) 2011-11-23
AU2009329811B2 (en) 2016-02-25
EP3381471A1 (en) 2018-10-03
EP3381471B1 (en) 2024-03-20
CA2747206C (en) 2018-04-24
BRPI0918103A2 (pt) 2016-07-05
HK1255227A1 (en) 2019-08-09
KR20110117659A (ko) 2011-10-27
JP5674677B2 (ja) 2015-02-25
AU2016200267A1 (en) 2016-02-11
JP6147704B2 (ja) 2017-06-14
ES2685895T3 (es) 2018-10-15
US9352034B2 (en) 2016-05-31
RU2011127333A (ru) 2013-01-27
US8475796B2 (en) 2013-07-02
CN102256621A (zh) 2011-11-23
CA2747206A1 (en) 2010-07-01
US20110287027A1 (en) 2011-11-24
JP2014224123A (ja) 2014-12-04
JP2017149740A (ja) 2017-08-31
US20130243791A1 (en) 2013-09-19
AU2016200267B2 (en) 2017-09-07
RU2016102346A (ru) 2018-11-20
EP2387418A4 (en) 2013-07-17
EP2387418B1 (en) 2018-06-13
US20160311896A1 (en) 2016-10-27
CN102256621B (zh) 2017-12-12
JP2012512814A (ja) 2012-06-07
EP3381471C0 (en) 2024-03-20
HK1255046A1 (zh) 2019-08-02
US9834599B2 (en) 2017-12-05
RU2630969C2 (ru) 2017-09-15
RU2016102346A3 (enExample) 2019-07-29

Similar Documents

Publication Publication Date Title
KR101761324B1 (ko) 통증 치료
US10005840B2 (en) Method for treatment of osteoarthritis with C-Fms antagonists
KR101799264B1 (ko) 골관절염 치료
HK1162335A (en) Pain treatment
HK1162335B (en) Pain treatment

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110720

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20141222

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160720

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170328

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160720

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170328

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20161025

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20141222

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20170502

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20170421

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20170328

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20161025

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20141222

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20170719

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20170720

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20200624

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20210628

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20220627

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240625

Start annual number: 8

End annual number: 8